A Novel Cytoprotective Peptide for GI Epithelial Cell

一种新型胃肠道上皮细胞细胞保护肽

基本信息

  • 批准号:
    6881136
  • 负责人:
  • 金额:
    $ 15.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-04-15 至 2006-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Disruption of intestinal barrier function may be a common pathogenetic mechanism that mediates morbidity and mortality in subjects with inflammatory bowel disease (IBD) and gut-derived sepsis (GDS). If so, a therapeutic strategy that protects mucosal barrier function and structure by increasing accumulation of tight and adhesion junction proteins that connect mucosal epithelial cells could be used to treat these conditions. We recently characterized a novel 18-kDa protein called AMP-18, that is synthesized in epithelial cells of the gastric antrum mucosa of humans and 6 other mammals, and has mitogenic and motogenic properties. A 21-mer peptide derived from the central domain of the protein was found to be cytoprotective in human colonic epithelial cell (Caco-2/bbe) cultures subjected to injury by an oxidant, indomethacin, or dextran sulfate sodium (DSS) used to induce colitis in mice, Studies in cell culture indicate that this AMP peptide activates p38 MAP kinase, increases accumulation of specific tight junction proteins (occludin, ZO-1, claudin-5), an adherens junction protein (E-cadherin), and heat shock proteins (hsp25, hsp72), and protects the actin microfilament network in cells exposed to cytochalasin D. When given to mice, AMP peptide increases the content of hyperphosphorylated occludin in the colonic mucosa. To determine if these biological effects of AMP peptide confer colonic cytoprotection in vivo, its effectiveness was tested in two important animal models of barrier compromise, IBD and GDS. Pretreatment of mice with AMP peptide delayed the onset of bloody diarrhea and reduced weight loss in animals given DSS to induce colitis. The peptide also prevented the death of mice given intracecal Pseudomonas aeruginosa following the surgical stress of partial hepatectomy and post-operative food deprivation in a model GDS. Our objective is to obtain additional support in cell culture and in vivo models of IBD and GDS to demonstrate that AMP peptide, by increasing accumulation of tight junction proteins such as occludin, protects colonic mucosal barrier structure and function. Studies that confirm and extend the cytoprotective, mitogenic, and motogenic effects of AMP peptide would lend further support to developing this molecule as a therapeutic agent to treat not only IBD and GDS, but other GI diseases mediated by disruption of intestinal tight junctions and the subsequent increase in mucosal permeability to bacteria and their products.
描述(申请人提供):肠屏障功能障碍可能是炎症性肠病(IBD)和肠源性脓毒症(GDS)患者发病和死亡的常见致病机制。如果是这样的话,一种通过增加连接粘膜上皮细胞的紧密和粘连连接蛋白的积累来保护粘膜屏障功能和结构的治疗策略可以用于治疗这些疾病。我们最近鉴定了一种名为AMP-18的新的18 kDa蛋白质,它是在人类和其他6种哺乳动物的胃窦粘膜上皮细胞中合成的,具有有丝分裂和运动发育特性。一种来自该蛋白中央结构域的21聚体多肽在人结肠上皮细胞(Caco-2/BBE)培养中被发现具有细胞保护作用,该细胞受到氧化剂、吲哚美辛或葡聚糖硫酸钠(DSS)的损伤,用于诱导小鼠结肠炎。细胞培养研究表明,这种AMP多肽激活p38 MAP激酶,增加特定紧密连接蛋白(occludin,ZO-1,claudin-5)、黏附连接蛋白(E-cadherin)和热休克蛋白(HSP25,Hsp72)的积聚,并保护暴露于细胞松弛素D的细胞中的肌动蛋白微丝网络。AMP肽可增加结肠粘膜中过度磷酸化的阻滞素的含量。为了确定AMP肽的这些生物学效应是否在体内提供了结肠细胞保护,我们在两个重要的屏障损害动物模型IBD和GDS上测试了它的有效性。用AMP多肽对小鼠进行预处理,可延缓给予DSS诱导结肠炎的动物的血性腹泻和体重减轻。在GDS模型中,这种多肽还可以防止在部分肝切除和术后食物剥夺的手术应激后,鞘内注射铜绿假单胞菌的小鼠死亡。我们的目标是在IBD和GDS的细胞培养和体内模型中获得额外的支持,以证明AMP肽通过增加紧密连接蛋白(如occludin)的积累来保护结肠粘膜屏障的结构和功能。证实和扩展AMP多肽的细胞保护、有丝分裂和运动生成作用的研究将进一步支持开发该分子作为治疗剂,不仅治疗IBD和GDS,而且还治疗其他由肠道紧密连接破坏和随后增加的粘膜对细菌及其产物的通透性所介导的胃肠道疾病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

FREDERICK Gary TOBACK其他文献

FREDERICK Gary TOBACK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('FREDERICK Gary TOBACK', 18)}}的其他基金

A Novel Agent with Dual Functions to Treat Head and Neck Cancer
一种具有双重功能的治疗头颈癌的新型药物
  • 批准号:
    8638361
  • 财政年份:
    2014
  • 资助金额:
    $ 15.25万
  • 项目类别:
A Novel Agent with Dual Functions to Treat Head and Neck Cancer
一种具有双重功能的治疗头颈癌的新型药物
  • 批准号:
    8777091
  • 财政年份:
    2014
  • 资助金额:
    $ 15.25万
  • 项目类别:
Targeting Tight Junctions To Treat Mucositis
针对紧密连接治疗粘膜炎
  • 批准号:
    7817005
  • 财政年份:
    2009
  • 资助金额:
    $ 15.25万
  • 项目类别:
Targeting Tight Junctions To Treat Mucositis
针对紧密连接治疗粘膜炎
  • 批准号:
    7660772
  • 财政年份:
    2009
  • 资助金额:
    $ 15.25万
  • 项目类别:
A Novel Cytoprotective Peptide for GI Epithelial Cell
一种新型胃肠道上皮细胞细胞保护肽
  • 批准号:
    6757728
  • 财政年份:
    2004
  • 资助金额:
    $ 15.25万
  • 项目类别:
BINDING OF CALCIUM CRYSTALS WITH RENAL CELLS
钙晶体与肾细胞的结合
  • 批准号:
    6600908
  • 财政年份:
    2002
  • 资助金额:
    $ 15.25万
  • 项目类别:
BINDING OF CALCIUM CRYSTALS WITH RENAL CELLS
钙晶体与肾细胞的结合
  • 批准号:
    6502964
  • 财政年份:
    2001
  • 资助金额:
    $ 15.25万
  • 项目类别:
BINDING OF CALCIUM CRYSTALS WITH RENAL CELLS
钙晶体与肾细胞的结合
  • 批准号:
    6349623
  • 财政年份:
    2000
  • 资助金额:
    $ 15.25万
  • 项目类别:
NOVEL GROWTH FACTOR RELEASED BY KIDNEY EPITHELIAL CELLS
肾上皮细胞释放的新型生长因子
  • 批准号:
    2141012
  • 财政年份:
    1987
  • 资助金额:
    $ 15.25万
  • 项目类别:
NOVEL GROWTH FACTOR RELEASED BY KIDNEY EPITHELIAL CELLS
肾上皮细胞释放的新型生长因子
  • 批准号:
    3239577
  • 财政年份:
    1987
  • 资助金额:
    $ 15.25万
  • 项目类别:

相似海外基金

A novel motility system driven by two classes of bacterial actins MreB
由两类细菌肌动蛋白 MreB 驱动的新型运动系统
  • 批准号:
    22KJ2613
  • 财政年份:
    2023
  • 资助金额:
    $ 15.25万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
EGF Receptor Endocytosis: Mechanisms and Role in Signaling
EGF 受体内吞作用:机制及其在信号传导中的作用
  • 批准号:
    10552100
  • 财政年份:
    2023
  • 资助金额:
    $ 15.25万
  • 项目类别:
Mitochondrial positioning regulates redox-signaling during cell migration
线粒体定位调节细胞迁移过程中的氧化还原信号
  • 批准号:
    10520211
  • 财政年份:
    2023
  • 资助金额:
    $ 15.25万
  • 项目类别:
Thick and Thin Filament Dysfunction in Obese Heart Failure with Preserved Ejection Fraction
射血分数保留的肥胖性心力衰竭的粗细丝功能障碍
  • 批准号:
    10678204
  • 财政年份:
    2023
  • 资助金额:
    $ 15.25万
  • 项目类别:
Mechanical signaling through the nuclear membrane in lung alveolar health
通过核膜的机械信号传导影响肺泡健康
  • 批准号:
    10677169
  • 财政年份:
    2023
  • 资助金额:
    $ 15.25万
  • 项目类别:
Cytoskeleton-mediated regulation of insulin secretion hot spots in pancreatic beta cells
细胞骨架介导的胰腺β细胞胰岛素分泌热点的调节
  • 批准号:
    10679903
  • 财政年份:
    2023
  • 资助金额:
    $ 15.25万
  • 项目类别:
Decoding dynamic interplay between signaling and membranes in chemotaxis bymolecular actuators
通过分子致动器解码趋化中信号传导和膜之间的动态相互作用
  • 批准号:
    10846921
  • 财政年份:
    2023
  • 资助金额:
    $ 15.25万
  • 项目类别:
Modulators of cardiomyocyte structure to promote functional recovery during cardiac regeneration and repair
心肌细胞结构调节剂促进心脏再生和修复过程中的功能恢复
  • 批准号:
    10751640
  • 财政年份:
    2023
  • 资助金额:
    $ 15.25万
  • 项目类别:
Selective actin remodeling of sensory neurons for acute pain management
感觉神经元的选择性肌动蛋白重塑用于急性疼痛管理
  • 批准号:
    10603436
  • 财政年份:
    2023
  • 资助金额:
    $ 15.25万
  • 项目类别:
Targeting the transcriptional co-activators YAP and TAZ with statins to prevent solid organ transplant rejection by HLA donor specific antibodies
用他汀类药物靶向转录共激活剂 YAP 和 TAZ,以防止 HLA 供体特异性抗体导致实体器官移植排斥
  • 批准号:
    10734277
  • 财政年份:
    2023
  • 资助金额:
    $ 15.25万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了